Gel buffer and method for capillary electrophoresis

By using gel buffer containing Tris, boric acid, dextran, glycerol, SDS and EDTA in capillary electrophoresis, the problem of difficult separation of protein drug impurities in the prior art is solved, and the resolution and detection accuracy are significantly improved , improves the ability of drug quality control.

CN118961852AInactive Publication Date: 2024-11-15BIO THERA SOLUTIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310548567.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-15
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing commercial reagents and platform-based methods cannot effectively detect impurities with small differences in molecular size in protein drugs, making it difficult to isolate and detect proteins and affect drug quality control.

Method used

Provide a gel buffer for capillary electrophoresis, containing components such as Tris, boric acid, dextran, glycerol, SDS and EDTA, to improve the resolution of the main peak and acromion by adjusting component concentration and pH and other parameters to improve the separation effect.

Benefits of technology

The resolution of the main peak and acromum is significantly improved, and the acromum impurities with small differences in molecular weight from the main peak are effectively separated and monitored, which improves the accuracy and reliability of drug quality analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961852A_ABST
    Figure CN118961852A_ABST
Patent Text Reader

Abstract

The present invention provides methods and gel buffers for capillary electrophoresis (CE) separation of proteins. The method or the gel buffer solution provided by the invention can improve the separation degree of a main peak and an acromion when protein is separated by capillary electrophoresis (CE).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method and a gel buffer for separating proteins by capillary electrophoresis (CE). Background Art

[0002] Capillary electrophoresis (CE) is an analytical method that uses a high-voltage direct current electric field as a driving force and a capillary as a separation channel. The commonly used sodium dodecyl sulfate-capillary electrophoresis (CE-SDS) is a gel-free sieving electrophoresis that uses a molecular sieve formed by a polymer solution in a capillary tube to separate proteins. During sample preparation, the protein sample and SDS are heated simultaneously, and SDS and the protein are proportionally combined to form a complex with a negatively charged conformation that tends to be linear. Regardless of the type of protein, it exhibits a consistent charge-to-mass ratio, and the mobility depends on the size of the protein. The sample is separated according to the different speeds of movement in the capillary according to the size of the molecular weight. Therefore, CE-SDS capillary electrophoresis has become an important means of analyzing molecular size isomers of various recombinant proteins such as monoclonal antibodies, bispecific antibodies, fusion proteins, and biological products such as antibody-drug conjugates (ADCs). At present, the industry has developed commercial reagents for this method and has platformized the method for routine analysis of various proteins.

[0003] Since there are many impurities with small molecular size differences in protein drugs, separation and detection are very difficult, and the current commercial reagents and platform methods are still unable to effectively detect such impurities. In addition, various regulatory authorities have gradually realized the problems that this technical bottleneck brings to drug quality control. Therefore, research on improving the separation degree of the CE-SDS method is of great significance for drug quality analysis. Summary of the invention

[0004] In one aspect, the present invention provides a gel buffer for use in capillary electrophoresis separation of a target protein in a sample. In some embodiments, the present invention provides a gel buffer for improving the resolution of a main peak and a shoulder peak when separating a protein sample by capillary electrophoresis.

[0005] In some embodiments, the gel buffer comprises one or more selected from a buffer component, a hydrophilic polymer, an organic additive, a detergent, a metal chelator, and any combination thereof.

[0006] In some embodiments, the gel buffer comprises a hydrophilic polymer. In some embodiments, the hydrophilic polymer is dextran, polyacrylamide, cellulose derivatives and polyethylene oxide. In some embodiments, the hydrophilic polymer is dextran (MW~2000kDa). In some embodiments, the dextran concentration is 11-20%. In some embodiments, the dextran concentration is 13-17%. In some embodiments, the dextran concentration is 15%.

[0007] In some embodiments, the buffer component comprises Tris (trishydroxymethylaminomethane), boric acid, phosphate, citrate, succinate and acetic acid, or any combination thereof. In some embodiments, the buffer component comprises Tris. In some embodiments, the buffer component comprises Tris and boric acid. In some embodiments, the buffer component comprises about 500-about 1000 mM Tris and about 500-about 900 mM boric acid. In some embodiments, the buffer component comprises about 500-about 1000 mM, about 600-about 900 mM, about 650-about 900 mM, about 700-about 900 mM, about 750-about 900 mM, about 800-about 900 mM, or about 850-about 900 mM Tris and about

[0008] In some embodiments, the buffer component comprises about 500-about 900mM, about 600-about 900mM, about 650-about 900mM, about 700-about 900mM, about 750-about 900mM, about 800-about 900mM, or about 850-about 900mM boric acid. In some embodiments, the buffer component comprises about 700mM-about 900mM Tris and about 650-about 900mM boric acid. In some embodiments, the buffer component comprises about 600mM Tris and about 600mM boric acid. In some embodiments, the buffer component comprises about 850mM Tris and about 700mM boric acid.

[0009] In some embodiments, the pH of the buffer is about 8.0-9.0. In some embodiments, the pH of the buffer is about 8.0. In some embodiments, the pH of the buffer is about 8.5.

[0010] In some embodiments, the organic additive is an alcohol, such as mannitol, glycerol, ethylene glycol, ethanol, methanol, or any combination thereof. In some embodiments, the concentration of the organic additive is about 0.1-about 30% v / v. In some embodiments, the organic additive is about 5-about 15% v / v glycerol. In some embodiments, the organic additive is about 10% v / v glycerol.

[0011] In some embodiments, the detergent is a hydrophobic detergent. In some embodiments, the hydrophobic detergent is selected from sodium dodecyl sulfate (SDS), sodium tridecyl sulfate, sodium tetradecyl sulfate (STS), sodium pentadecyl sulfate, sodium hexadecyl sulfate (SHS), sodium heptadecanyl sulfate, and sodium octadecyl sulfate (SOS). In some embodiments, the detergent is present in an amount of about 0.1-about 2% w / v. In some embodiments, the detergent is present in an amount of about 0.2-about 2% w / v. In some embodiments, the detergent is present in an amount of about 0.5-about 2% w / v.

[0012] In some embodiments, the metal chelator is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DPTA) or any combination thereof. In some embodiments, the content of the metal chelator is about 2-about 15mM. In some embodiments, the content of the metal chelator is about 5-about 15mM.

[0013] In some embodiments, the gel buffer comprises Tris, boric acid, dextran, glycerol, SDS, and EDTA.

[0014] In some embodiments, the gel buffer comprises about 500-about 900 mM Tris, about 500-about 900 mM boric acid, about 12-about 20% w / v dextran, about 5-about 15% v / v glycerol, about 0.1-about 2% w / v SDS, and about 2-about 15 mM EDTA.

[0015] In some embodiments, the gel buffer comprises about 600-about 900 mM Tris, about 600-about 900 mM boric acid, about 13-about 20% w / v dextran, about 5-about 15% v / v glycerol, about 0.2-about 2% w / v SDS, and about 5-about 15 mM EDTA.

[0016] In some embodiments, the gel buffer comprises about 600-about 900 mM Tris, about 600-about 900 mM boric acid, about 13-about 20% w / v dextran, about 5-about 15% v / v glycerol, about 0.5-about 2% w / v SDS, and about 5-about 15 mM EDTA.

[0017] In some embodiments, the gel buffer comprises about 600 mM Tris, about 600 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA.

[0018] In some embodiments, the gel buffer comprises about 850 mM Tris, about 700 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA.

[0019] On the other hand, the present invention provides a method for separating protein samples by capillary electrophoresis, comprising first adding the gel buffer provided by the present invention into a capillary, injecting the protein sample, separating, and detecting.

[0020] In some embodiments, the methods of the present invention comprise the following steps:

[0021] (1) preparing protein samples;

[0022] (2) preparing the gel buffer solution;

[0023] (3) Capillary electrophoresis experiment: first add gel buffer into the capillary, inject the protein sample, separate and detect.

[0024] In some embodiments, step (1) comprises denaturing the protein in a sample buffer.

[0025] In some embodiments, the denaturation is performed at a temperature of at least about 60°C, at least about 65°C, at least about 70°C, at least about 75°C, or at least about 80°C. In some embodiments, the denaturation is performed at a temperature of about 60°C to about 70°C, about

[0026] The denaturation is carried out at a temperature of about 65° C. to about 70° C., or about 60° C. to about 65° C. In some embodiments, the denaturation is carried out for at least about 3 minutes, at least about 4 minutes, at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9 minutes, at least about 10 minutes.

[0027] In some embodiments, the concentration of the protein sample in step (1) is about 0.25 to about 1 mg / mL. In some embodiments, the concentration of the protein sample in step (1) is about 1 mg / mL.

[0028] In some embodiments, the inner diameter of the capillary is about 25 μm-100 μm. In some embodiments, the inner diameter of the capillary is about 50 μm.

[0029] In some embodiments, in step (3), the capillary electrophoresis experiment uses a non-coated quartz capillary with an effective length of 23-32 cm, such as 24.5 cm and 28.5 cm, and an inner diameter of 50 μm.

[0030] In some embodiments, in step (3), the separation voltage during the capillary electrophoresis experiment is 10 kV-17 kV, such as 16.5 kV, 14 kV, 12 kV or 10 kV.

[0031] In some embodiments, in step (3), a diode array detector (DAD detector) is used for detection, and the detection wavelength is 220 nm.

[0032] In some embodiments, in step (3), the capillary electrophoresis experiment uses a non-coated quartz capillary with an effective capillary length of 28.5 cm and an inner diameter of 50 μm, and the separation voltage of the capillary electrophoresis experiment is 10 kV.

[0033] In some embodiments, the protein is an antibody. In some embodiments, the antibody is an isotype selected from IgM, IgA, IgE, IgD and IgG. In some embodiments, the IgG antibody is selected from IgG1, IgG2, IgG3 and IgG4. In some embodiments, the protein includes enzymes, hormones, cytokines, cell surface receptors, proteases, cytokine receptors, antibodies (e.g., monoclonal antibodies, bispecific antibodies, multispecific antibodies, only heavy chain antibodies or nano antibodies), antibody drug conjugates (ADC) or any combination thereof. In some embodiments, the protein is a fusion protein. In some embodiments, the fusion protein is fused with a heterologous part. In some embodiments, the heterologous part is a part that extends the half-life. In some embodiments, the part that extends the half-life includes Fc. In some embodiments, the antibody is a monoclonal antibody, a bispecific antibody, a multispecific antibody, only heavy chain antibodies or nano antibodies. In some embodiments, the protein is bevacizumab.

[0034] In some embodiments, the molecular weight of the protein is in the range of 10-200 kDa. In some embodiments, the molecular weight of the protein analyzed by the method of the present invention is about 10 kD, about 15 kD, about 20 kD, about 25 kD, about 30 kD, about 35 kD, about 40 kD, about 50 kD, about 60 kD, about 70 kD, about 80 kD, about 90 kD, about 100 kD, about 110 kD, about 120 kD, about 130 kD, about 140 kD, about 150 kD, about 160 kD, about 170 kD, about 180 kD, about 190 kD or about 200 kD.

[0035] In some embodiments, the gel buffer is used for reducing CE-SDS. In some embodiments, the gel buffer is used for non-reducing CE-SDS (nrCE-SDS).

[0036] The nrCE-SDS method of the present invention can significantly improve the separation degree between the main peak and the shoulder peak, and effectively separate and monitor the shoulder peak impurities with a smaller molecular weight difference from the main peak. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The nrCE-SDS detection spectra of mAb1 samples with different concentrations are shown, where 1 mg / mL, 2 mg / mL, 3 mg / mL, and 4 mg / mL are the sample concentrations of mAb1.

[0038] Figure 2 The nrCE-SDS detection spectrum of mAb1 sample at different capillary effective lengths is shown, where 24.5 cm and 28.5 cm represent the capillary effective lengths, respectively.

[0039] Figure 3 The nrCE-SDS detection spectrum of mAb1 sample under different separation voltages is shown, where 16.5 kV, 14 kV, 12 kV, and 10 kV represent the separation voltages.

[0040] Figure 4 The nrCE-SDS detection spectra of mAb1 samples at different dextran concentrations are shown, where 9%, 12%, and 15% represent dextran concentrations (w / v).

[0041] Figure 5 The nrCE-SDS comparison spectrum of mAb1-STD is shown. The left side represents method 1 (ordinary method), the right side represents method 2, HL is an impurity containing 1 heavy chain and 1 light chain, HH is an impurity containing two heavy chains, and HHL is an impurity containing two heavy chains and 1 light chain.

[0042] Figure 6 The nrCE-SDS comparison spectrum of the sample (mAb1-GW-14d) of mAb1 after high temperature degradation is shown. The left side represents method 1 (ordinary method), the right side represents method 2, HL is an impurity containing 1 heavy chain and 1 light chain, HH is an impurity containing two heavy chains, and HHL is an impurity containing two heavy chains and 1 light chain.

[0043] Figure 7 The nrCE-SDS comparison spectrum of bevacizumab mAb2 samples is shown. The left side represents method 1 (ordinary method), the right side represents method 2, HL is an impurity containing 1 heavy chain and 1 light chain, HH is an impurity containing two heavy chains, and HHL is an impurity containing two heavy chains and 1 light chain.

[0044] Figure 8The nrCE-SDS comparison spectrum of bevacizumab mAb3 samples is shown. The left side represents method 1 (ordinary method), the right side represents method 2, HL is an impurity containing 1 heavy chain and 1 light chain, HH is an impurity containing two heavy chains, and HHL is an impurity containing two heavy chains and 1 light chain. DETAILED DESCRIPTION

[0045] The technical solution of the present invention is further described below by specific embodiments, which do not limit the protection scope of the present invention. Some non-essential modifications and adjustments made by others based on the concept of the present invention still fall within the protection scope of the present invention.

[0046] the term

[0047] Weight volume (w / v) percentage, where the weight unit can be g and the volume unit can be ml. For example, 1% w / v SDS in a solution means that 100 ml of the solution contains 1 g of SDS, or the SDS content is 0.01 g / ml.

[0048] "About" refers to the conventional error range of the corresponding numerical value that is easily known to those skilled in the relevant art. In some embodiments, "about" mentioned herein refers to the described numerical value and its ±10%, ±5%, ±1% or ±0.1% range.

[0049] The term "separation" refers to separating the protein components in a sample (including one or more target proteins and one or more impurities) in order to detect the purity of the target protein in the sample and the type and content of the impurities. Separation can be performed via electrophoresis, in which an electric field is used to pass negatively charged particles through a substance. When the particles have the same uniform charge, they migrate through the electric field according to their size, and the different mobilities cause the particles including the target protein to be separated.

[0050] The term "buffer" refers to a solution that resists changes in pH through the action of its acid-base coupled components.

[0051] The term "sample buffer" refers to a buffer added to a protein sample in preparation for running the sample on a gel for electrophoretic analysis. Buffer solutions resist changes in pH through the action of their acid-base conjugate components. Sample buffers may contain detergents to denature proteins and render them negatively charged.

[0052] The term "gel buffer" refers to a composition added to an electrophoresis apparatus (such as a capillary) for separating proteins. In some embodiments, the gel buffer comprises one or more additional components selected from a buffer component, an organic additive, a hydrophilic polymer, a metal chelator, and any combination thereof.

[0053] In some embodiments, the detergent is sodium dodecyl sulfate (SDS), which has been widely used in protein denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and capillary gel electrophoresis using sodium dodecyl sulfate (CE-SDS) techniques, which can be attributed to the generally recognized fact that proteins tend to bind to a relatively constant amount of SDS on a weight basis (~1.4g SDS / 1g protein), thereby producing a uniform mass-to-charge ratio of the SDS-protein complex in most cases. Therefore, the intrinsic polypeptide charge of the protein molecule becomes negligible, and the final separation depends entirely on the difference in the relative molecular weight of its denatured polypeptides.

[0054] In some embodiments, the detergent is a hydrophobic detergent. In some embodiments, the hydrophobic detergent can also be sodium tridecyl sulfate, sodium tetradecyl sulfate (STS), sodium pentadecyl sulfate, sodium hexadecyl sulfate (SHS), sodium heptadecanyl sulfate, and sodium octadecyl sulfate (SOS). In some embodiments, the concentration of the hydrophobic detergent in the sample buffer or gel is about 0.001% to about 4% w / v. In some embodiments, the concentration of the hydrophobic detergent can be about 0.001%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about

[0055] 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9% or about 3.0%.

[0056] In some embodiments, examples of buffer components include, but are not limited to, tris(hydroxymethyl)aminomethane (Tris), boric acid, phosphate, citrate, succinate, and acetic acid, or any combination thereof. In some embodiments, the buffer component includes Tris. In some embodiments, the buffer component includes Tris and boric acid. In some embodiments, the buffer component comprises about 500-about 1000 mM Tris and about 500-about 900 mM boric acid. In some embodiments, the buffer component comprises about 500-about 1000mM, about 600-about 900mM, about 650-about 900mM, about 700-about 900mM, about 750-about 900mM, about 800-about 900mM, or about 850-about 900mM Tris and about 500-about 900mM, about 600-about 900mM, about 650-about 900mM, about 700-about 900mM, about 750-about 900mM, about 800-about 900mM, or about 850-about 900mM boric acid. In some embodiments, the buffer component comprises about 600mM-about 900mM Tris and about 600-about 700mM boric acid. In some embodiments, the buffer component comprises about 600mM Tris and about 600mM boric acid. In some embodiments, the buffer component comprises about 850 mM Tris and about 700 mM boric acid.

[0057] In some embodiments, the organic additive includes mannitol, glycerol, ethylene glycol, ethanol, methanol, propylene glycol, monomethyl ether of diethylene glycol, dimethyl ether of diethylene glycol, methyl carbitol, tetrahydrofuran, dibutyl ether, dimethylformamide, sulfolane, or alcohols having 1-4 carbon atoms, or any combination thereof.

[0058] In some embodiments, the hydrophilic polymer includes dextran, polyacrylamide, polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol or any combination thereof. In some embodiments, the hydrophilic polymer is dextran (MW~2000kDa). In some embodiments, the hydrophilic polymer is dextran T2000. In some embodiments, the dextran concentration is about 11-about 20%. In some embodiments, the dextran concentration is about 13-about 17%. In some embodiments, the dextran concentration is about 15%.

[0059] In some embodiments, the metal chelator includes ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), ethylene glycoltetraacetic acid (EGTA), trisodium nitrilotriacetate, trisodium hydroxyethylethylenediamineacetate (trisodium HEDTA), pentasodium diethylenetriaminoacetate or disodium 2-aminomalonylurea acetate (uramil disodium acetate) or any combination thereof. The concentration range of metal chelators such as EDTA that can be used to prepare the electrophoresis gel buffer of the present invention is about 5mM to about 15mM.

[0060] The term "impurity" is used in its broadest sense to cover any undesirable component or compound within a mixture. In cell culture, cell lysate or clarified bulk (e.g., clarified cell culture supernatant), impurities include, for example, host cell nucleic acids (e.g., DNA) and host cell proteins present in the cell culture medium. Host cell impurity proteins include, but are not limited to, proteins produced naturally or recombinantly by host cells, as well as proteins related to or derived from the target protein (e.g., proteolytic fragments) and impurities related to other processes.

[0061] The term "abundance" refers to the amount of a substance, such as an impurity or a protein of interest.

[0062] As used herein, the term "protein" is used in its broadest sense and includes any protein (natural or recombinant) present in a mixture that needs to be purified. Such proteins include, but are not limited to, enzymes, hormones, growth factors, cytokines, immunoglobulins (e.g., antibodies), and / or any fusion proteins. In some embodiments, the antibodies include monoclonal antibodies, bispecific antibodies, multispecific antibodies, heavy chain antibodies only, or nanobodies.

[0063] In some embodiments, the protein is an antibody. In some embodiments, the antibody is an isotype selected from IgM, IgA, IgE, IgD, and IgG. In some embodiments, the IgG is selected from IgG1, IgG2, IgG3, and IgG4.

[0064] In some embodiments, an alkylating agent is added under non-reducing and partially reducing CE-SDS conditions to prevent antibody molecule fragmentation caused by disulfide bond disruption. In some embodiments, the alkylating agent comprises iodoacetamide (IAM), N-ethylmaleimide (NEM), chloroacetamide.

[0065] In some embodiments, IgG molecules are treated with a reducing agent (e.g., β-mercaptoethanol (BME)) under reducing conditions to cleave disulfide bonds, and protein fragments including light chain (LC), heavy chain (HC), and non-glycosylated heavy chain (NGHC) are separated by size and electrophoretic mobility.

[0066] In some embodiments, denaturation can be performed at a temperature of at least about 60° C., at least about 65° C., at least about 70° C., at least about 75° C., or at least about 80° C., e.g., a temperature of about 60° C. to about 70° C., about 65° C. to about 70° C., or about 60° C. to about 65° C. In some embodiments, denaturation is performed for at least about 3 minutes, at least about 4 minutes, at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9 minutes, or at least about 10 minutes.

[0067] Shoulder peak: A small inflection that does not form a peak shape appears on the peak of the elution curve or absorption curve. Its shape is similar to a shoulder, so it is called a shoulder peak. It is usually an impurity peak that is different from the main substance (main peak) but cannot be baseline separated due to the limitation of the method separation degree.

[0068] Shoulder peak "separation rate" or "resolution" is a quantitative measure of the degree to which two eluting peaks can be distinguished in a chromatographic separation. It is defined as the difference in retention time between the two peaks divided by the sum of the widths of the eluting peaks, expressed as follows: R = 2 (R t2 –R t1 ) / (W 2 +W 1 ). Where R = resolution between two peaks, R t1 and R t2 are the retention / migration times of peaks 1 and 2, respectively, 2 +W 1 is the sum of the peak widths at the baseline, with a tangent line drawn at 50% of the peak height.

[0069] In the following examples, unless otherwise specified, the reagents and instruments used are conventional reagents and instruments in the art and can be obtained commercially; the methods used are conventional technical methods in the art, and those skilled in the art can undoubtedly implement the methods and obtain corresponding results based on the contents of the examples.

[0070] The protein samples used in the following examples are bevacizumab samples, for example, mAb1 (BAT1706, manufactured by Bio-Thera), mAb2 and mAb3 are bevacizumab samples commercially available from other manufacturers.

[0071] Example 1

[0072] Reagents: Glycerol (Cat. No. G5516), Tris base ( Alkali (catalog number: T1503), boric acid (catalog number: B6768), ethylenediaminetetraacetic acid (EDTA, catalog number: V900106) and iodoacetamide (IAM, catalog number: V900335) were purchased from Sigma; sodium dodecyl sulfate (SDS, catalog number: S108346) was purchased from Aladdin; dextran (Dextran T2000, catalog number: 5510 20009006, Mw ~ 2000 kDa) was purchased from PHARMACOSMOS. Commercially available SDS-MW gel buffer (Beckman, catalog number: A30341).

[0073] Capillary electrophoresis: CE-SDS experiment was performed using a capillary electrophoresis instrument (Agilent / CE7100), with a diode array detector (DAD) for detection at a wavelength of 220 nm; the inner diameter of the capillary (non-coated quartz capillary) was 50 μm, the effective length was selected from 24.5 and 28.5 cm, and the capillary temperature was 25° C. The electrophoresis separation voltage was selected from 16.5 kV, 14 kV, 12 kV, and 10 kV.

[0074] The sample buffer was formulated as follows: 40 mM Na 2 HPO 4 -Citrate buffer solution + 1% w / v SDS, pH 6.5. After the protein is added to the sample buffer, it binds to SDS, denatures and forms a complex with a linear conformation.

[0075] Preparation of non-reduced protein samples: Dilute an appropriate amount of protein sample with ultrapure water to a certain concentration (normal concentration is 4 mg / mL), take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25M iodoacetamide to form a test sample with a protein concentration of 1 mg / mL. After mixing, centrifuge the liquid in the tube to the bottom of the tube and place in a 65°C water bath for 5 minutes (min). After cooling to room temperature, centrifuge all the liquid to the bottom of the tube again, mix well and transfer to the sample bottle for testing.

[0076] The gel buffer was prepared by mixing Trizma base, boric acid, EDTA and glycerol together, followed by the addition of SDS and dextran. The formula of the gel buffer is shown in Table 1:

[0077] Table 1 Gel buffer formula

[0078] Element Recipe A Recipe B Recipe C Recipe D Trizma(mM) 600 600 600 850 Boric acid (mM) 600 600 600 700 Dextran (w / v) 9% 12% 15% 15% Glycerol (v / v) 10% 10% 10% 10% SDS(w / v) 0.5% 0.5% 0.5% 0.5% EDTA(mM) 5 5 5 5 pH 8.0 8.0 8.0 8.5

[0079] Example 2: Effect of sample concentration on method resolution

[0080] The CE-SDS detection method mainly uses electrokinetic injection. The ionic strength in the solution and the sample concentration (sample concentration refers to the concentration of protein in the sample) will affect the injection volume. The conventional sample concentration is 4 mg / mL, and the test sample protein concentration is 1 mg / mL. This example examines the effect of the injection volume on the separation of the method by changing the sample concentration.

[0081] Preparation of non-reduced protein test solution: Dilute the appropriate amount of protein sample mAb1 to 1, 2, 3 or 4 mg / mL with ultrapure water, take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25M iodoacetamide, mix well, centrifuge the liquid in the tube to the bottom of the tube, and then bathe at 65℃ for 5 minutes to obtain test samples with protein concentrations of 0.25, 0.5, 0.75, and 1 mg / mL. After the test sample is cooled to room temperature, centrifuge all the liquid to the bottom of the tube again, mix well, and transfer to the sample bottle for testing. Samples of different concentrations were tested under the same capillary electrophoresis conditions, and the detection method parameters were set as shown in the following table.

[0082] Table 2 Some parameter settings of the detection method

[0083] Method Parameters Test conditions Sample concentration (mg / mL) 1、2、3、4 Test sample concentration (mg / mL) 0.25、0.5、0.75、1 Capillary effective length (cm) 24.5 Separation voltage(kV) 16.5 Gel Buffer Formulation Recipe A

[0084] The results are shown in Table 3 and Figure 1 shown. Figure 1 In the detection spectrum shown, it can be clearly seen that there is a shoulder peak on the left side of the main peak. The separation degree of this shoulder peak is only 0.34 at the normal sample concentration (4 mg / mL) (Table 3). As the sample concentration decreases, the separation degree between the main peak and the shoulder peak gradually increases. When the sample concentration is 1 mg / mL (that is, the test sample concentration is 0.25 mg / mL), the separation degree reaches 0.82.

[0085] As the separation increases, the amount of shoulder peaks monitored also increases. Moreover, the decrease in sample concentration will inevitably lead to a decrease in the sensitivity of the detection method to low-abundance components in the sample. Therefore, in order to ensure that low-abundance components in the sample can also be accurately quantified, the sample protein concentration remains unchanged.

[0086] Table 3 nrCE-SDS detection results of samples with different concentrations

[0087] Sample concentration (mg / mL) Main peak and shoulder peak separation Main peak percentage (%) Shoulder peak percentage (%) 1 0.82 88.91 7.33 2 0.54 89.81 6.10 3 0.40 90.41 5.46 4 0.34 90.61 5.20

[0088] Example 3: Effect of effective capillary length on method resolution

[0089] Due to the action of the denaturant SDS, the higher-order structure of the protein is opened and linear and negatively charged at a fixed ratio, so the movement speed of the protein in the capillary depends on its molecular weight. In theory, when the relative movement speed of molecules of different sizes in the electric field is constant, the distance between them can be increased by extending their movement distance, thereby improving the separation degree of the method.

[0090] Preparation of non-reduced protein samples: Dilute an appropriate amount of protein sample mAb1 to 4 mg / mL with ultrapure water, take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide, and the concentration of the test sample is 1 mg / mL. After mixing, centrifuge the liquid in the tube to the bottom of the tube and then bathe in 65°C water for 5 minutes. After cooling to room temperature, centrifuge all the liquid to the bottom of the tube again, mix well and transfer to the sample bottle for testing. The effective lengths of the capillaries are 24.5 cm and 28.5 cm respectively, and other detection conditions are the same. The detection method parameter settings are shown in Table 4.

[0091] Table 4 Some parameter settings of the detection method

[0092] Method Parameters Test conditions Sample concentration (mg / mL) 4 Capillary effective length (cm) 24.5,28.5 Separation voltage(kV) 16.5 Gel Buffer Formulation Recipe A

[0093] The results are as follows Figure 2 As shown in Table 5, the experimental results show that the resolution is improved from 0.34 to 0.45.

[0094] Table 5 nrCE-SDS test results of different capillary effective lengths

[0095] Effective length (cm) Main peak and shoulder peak separation Main peak percentage (%) Shoulder peak percentage (%) 28.5 0.45 91.04 5.54 24.5 0.34 90.61 5.20

[0096] Example 4: Effect of separation voltage on method resolution

[0097] By changing the electric field to increase the relative speed difference between molecules, the separation between them can be improved. The effect of electric field change on the separation degree of the method can be explored by changing the separation voltage.

[0098] Preparation of non-reduced protein samples: Dilute an appropriate amount of protein sample mAb1 to 4 mg / mL with ultrapure water, take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25M iodoacetamide, and the test sample concentration is 1 mg / mL. After mixing, centrifuge the liquid in the tube to the bottom of the tube and then bathe in 65°C water for 5 minutes. After cooling to room temperature, centrifuge all the liquid to the bottom of the tube again, mix well and transfer to the sample bottle for testing. Set the separation voltage of capillary electrophoresis to 16.5 kV, 14 kV, 12 kV, and 10 kV respectively. Other detection conditions are the same. The detection method parameter settings are shown in Table 6.

[0099] Table 6 Some parameter settings of the detection method

[0100] Method Parameters Test conditions Sample concentration (mg / mL) 4 Capillary effective length (cm) 24.5 Separation voltage(kV) 16.5,14,12,10 Gel Buffer Formulation Recipe A

[0101] The results are as follows Figure 3 As shown in Table 7. The experimental results show that when the separation voltage is reduced from 16.5 kV to 10 kV, the separation degree is improved to a certain extent, but the improvement effect is limited. In addition, due to the reduction in the separation voltage, the protein movement speed is reduced, and the separation time is also increased.

[0102] Table 7 nrCE-SDS detection results at different separation voltages

[0103] Separation voltage Main peak and shoulder peak separation Main peak percentage (%) Shoulder peak percentage (%) 10kV 0.40 90.31 5.22 12kV 0.37 90.65 5.16 14kV 0.37 90.41 5.25 16.5kV 0.34 90.61 5.20

[0104] Example 5: Effect of Dextran Concentration in Gel Buffer on Method Resolution

[0105] Preparation of non-reduced protein samples: dilute an appropriate amount of protein sample mAb1 to 4 mg / mL with ultrapure water, take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25M iodoacetamide, and the test sample concentration is 1 mg / mL. After mixing, centrifuge the liquid in the tube to the bottom of the tube and place in a 65°C water bath for 5 minutes. After cooling to room temperature, centrifuge all the liquid to the bottom of the tube again, mix well and transfer to a sample bottle for testing. Gel buffers with different formulations were used for testing, and other detection conditions were the same. The concentrations of glucan in gel buffer formulations A, B, and C were 9%, 12%, and 15%, respectively. The detection method parameter settings for this test are shown in the following table.

[0106] Table 8 Detection method parameter settings

[0107] Method Parameters Test conditions Sample concentration (mg / mL) 4 Capillary effective length (cm) 24.5 Separation voltage(kV) 10 Gel buffer formula name Recipe A, B, C

[0108] The experimental results are as follows Figure 4 As shown in Table 9, the results show that when the concentration of dextran in the gel buffer increased from 9% to 15%, the resolution was significantly improved, and the resolution of formulation C was 1.5 times that of formulation A.

[0109] Table 9 nrCE-SDS detection results of gel buffer with different dextran concentrations

[0110] formula Main peak and shoulder peak separation Main peak percentage (%) Shoulder peak percentage (%) C 0.52 89.92 5.35 B 0.33 90.40 5.25 A 0.34 90.61 5.20

[0111] Example 6: Comparison of test results of method 2 and common method (method 1)

[0112] Preparation of non-reduced protein samples: Dilute appropriate amounts of protein samples mAb1, mAb1-GW-14d (mAb1 after forced degradation at high temperature), mAb2, and mAb3 to 4 mg / mL with ultrapure water, take 25 μL of the dilution, add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide to obtain a test sample with a protein concentration of 1 mg / mL.

[0113] After the test sample is mixed, the liquid in the tube is centrifuged to the bottom of the tube and then placed in a 65℃ water bath for 5 minutes. After cooling to room temperature, the liquid is centrifuged again to the bottom of the tube, mixed and transferred to the sample bottle for testing. The samples are tested using method 1 and method 2 respectively. The test method parameter settings are shown in the following table.

[0114] Table 10 Detection method parameter settings

[0115]

[0116] By using method 2 and the original common method 1 to test different samples at the same time, the difference in separation between the different methods was compared. The results are as follows Figure 5-8 As shown in Table 11. For the mAb1 standard (mAb1-STD), the impurity content is very low, and the shoulder peak cannot be separated by method 1, while the shoulder peak can be clearly separated by method 2 with a resolution of 0.66; in addition, for the mAb1 high temperature treated sample (mAb1-GW-14d), the resolution of method 2 is increased by 1 times; for mAb2 and mAb3, the resolution of method 2 is more than 2.8 times that of the original method.

[0117] The method provided in this paper can effectively improve the resolution of the CE-SDS detection method, and the resolution of the main peak and shoulder peak of different samples is stable at about 0.7. The method in this paper can significantly improve the resolution of the main peak and impurities, and effectively separate and monitor shoulder peak impurities with a small molecular weight difference from the main peak. The gel buffer in this paper can make the detection method more robust, repeatable and stable.

[0118] Table 11 Comparison of separation of samples in different detection methods

[0119] sample Method 1 Resolution Method 2 Separation mAb1-STD N / A 0.66 mAb1-GW-14d 0.34 0.69 mAb2 0.22 0.63 mAb3 0.38 1.11

Claims

1. A gel buffer comprising: a buffer component, a hydrophilic polymer, an organic additive, a detergent, and a metal chelating agent.

2. The gel buffer according to claim 1, wherein the hydrophilic polymer is selected from dextran, polyacrylamide, cellulose derivatives and polyethylene oxide; preferably, the hydrophilic polymer is dextran with a molecular weight of about 2000 kDa; preferably, the concentration of the dextran is about 11%-about 20% w / v.

3. The gel buffer according to claim 1 or 2, wherein the buffer component comprises Tris; preferably, the buffer component comprises Tris and boric acid; Preferably, the buffer component comprises about 500 to about 1000 mM Tris and about 500 to about 900 mM boric acid.

4. The gel buffer according to any one of claims 1 to 3, wherein the organic additive is an alcohol; preferably, the organic additive is glycerol; preferably, the concentration of the glycerol is about 5 to about 15% v / v.

5. The gel buffer according to any one of claims 1 to 4, wherein the detergent is selected from the group consisting of sodium dodecyl sulfate, sodium tridecyl sulfate, sodium tetradecyl sulfate, sodium pentadecyl sulfate, sodium hexadecyl sulfate, sodium heptadecyl sulfate and sodium octadecyl sulfate; preferably, the detergent is sodium dodecyl sulfate; preferably, the concentration of the sodium dodecyl sulfate is about 0.1-about 2% w / v.

6. The gel buffer according to any one of claims 1 to 5, wherein the metal chelator is selected from EDTA, DTPA or any combination thereof; preferably, the metal chelator is EDTA; preferably, the concentration of EDTA is about 2 to about 15 mM.

7. A gel buffer comprising about 500 to about 900 mM Tris, about 500 to about 900 mM boric acid, about 12 to about 20% w / v dextran, about 5 to about 15% v / v glycerol, about 0.1 to about 2% w / v SDS, and about 2 to about 15 mM EDTA; Alternatively, it comprises about 600 to about 900 mM Tris, about 600 to about 900 mM boric acid, about 13 to about 20% w / v dextran, about 5 to about 15% v / v glycerol, about 0.2 to about 2% w / v SDS, and about 5 to about 15 mM EDTA; Alternatively, it comprises about 600 mM Tris, about 600 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA; Alternatively, it comprises about 850 mM Tris, about 700 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS and about 5 mM EDTA.

8. Use of the gel buffer according to any one of claims 1 to 7 for CE-SDS detection of protein samples; preferably, the CE-SDS is non-reduced CE-SDS.

9. A method for separating a protein sample by capillary electrophoresis, comprising the following steps: First, add the gel buffer according to any one of claims 1 to 7 into the capillary, inject the protein sample, separate and detect.

10. The method according to claim 9, wherein the capillary has an effective length of about 23 cm to about 30 cm, such as about 24.5 cm or about 28.5 cm, and is a non-coated quartz capillary with an inner diameter of about 50 μm.

11. The method according to claim 9 or 10, wherein the capillary electrophoresis separation voltage is about 10 kV to about 17 kV, such as about 16.5 kV, about 14 kV, about 12 kV or about 10 kV.

12. The method according to claims 9-11, wherein the capillary electrophoresis is detected using a diode array detector with a detection wavelength of about 220 nm.

13. The method according to claims 9-12, further comprising preparing a protein sample.

14. The method according to claims 9-13, further comprising preparing the gel buffer according to any one of claims 1-7.